Premium
Epidermolysis bullosa pruriginosa treated with dupilumab
Author(s) -
Zhou Amanda G.,
Little Alicia J.,
Antaya Richard J.
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14493
Subject(s) - dupilumab , medicine , prurigo nodularis , dermatology , adverse effect , epidermolysis bullosa , quality of life (healthcare) , atopic dermatitis , nursing
Epidermolysis bullosa pruriginosa (EBP) is a variant of dystrophic epidermolysis bullosa characterized by intense pruritus and prurigo nodularis‐like lesions. While medical therapies for EBP exist, current treatments are not consistently effective, and symptoms often cause decreased quality of life. Here, we report two cases of EBP treated with dupilumab, which decreased symptoms of pruritus and improved skin findings. Both patients have been on dupilumab for over one year with sustained improvement and no adverse effects; although in one patient, increased dosing was required to attain optimal control of disease.